|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 2. Wnt5a inhibits ductal extension accompanied by diminished terminal end
bud size and proliferation. (A) A representative whole-mount image
of a #4 inguinal mammary gland with BSA pellet (P) depicts normal ductal
extension through the fat pad. Horizontal arrow represents the distance from
the lymph node to the end of the TEB. (B) A whole-mount image of the
gland contralateral to the one shown in A illustrates the inhibition of ductal
extension through the fat pad by Wnt5a pellet (P). (C) Quantification
of ductal inhibition from 11 mice using a paired Student's t-test
demonstrates that the inhibition is statistically significant
(P<0.05). (D) Magnification of the terminal end bud size
from control glands in A depicts the normal size of the end buds during
puberty. (E) Magnification of the end buds in B demonstrates the
smaller size of the end buds after Wnt5a exposure. (F,G) H&E
staining of the terminal end buds from the BSA (F) and Wnt5a (G) groups
illustrates the reduction in size of the terminal end buds with Wnt5a.
(H) BrdU incorporation in the end bud. Exposure to Wnt5a resulted in a
fourfold decrease in proliferation in the terminal end buds. Significance was
determined by a Student's t-test (P<0.05). Representative
images are shown to the right of the graph. (I) There was no
statistically significant difference in apoptosis within the terminal end
buds, determined by TUNEL staining.
|
